Van ECK Associates Corp Cuts Stake in Charles River Laboratories International, Inc. $CRL

Van ECK Associates Corp trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 28.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 26,210 shares of the medical research company’s stock after selling 10,616 shares during the quarter. Van ECK Associates Corp’s holdings in Charles River Laboratories International were worth $5,944,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in CRL. Jones Financial Companies Lllp boosted its position in shares of Charles River Laboratories International by 167.6% during the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after buying an additional 1,074 shares during the last quarter. Empowered Funds LLC bought a new stake in Charles River Laboratories International during the first quarter valued at approximately $418,000. American Century Companies Inc. grew its position in shares of Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after acquiring an additional 1,616 shares during the period. Brown Advisory Inc. grew its holdings in Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after purchasing an additional 114 shares during the period. Finally, California Public Employees Retirement System grew its stake in shares of Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after acquiring an additional 3,198 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Up 3.3%

NYSE CRL opened at $291.79 on Thursday. The company has a market capitalization of $13.93 billion, a price-to-earnings ratio of -60.16, a price-to-earnings-growth ratio of 2.77 and a beta of 1.40. The company’s 50-day simple moving average is $251.93 and its two-hundred day simple moving average is $199.91. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $303.30.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.33 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on CRL. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Barclays reissued an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Morgan Stanley boosted their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research note on Monday, August 10th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $255.65.

Insider Activity

In related news, CAO Michael Gunnar Knell sold 6,645 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the sale, the chief accounting officer owned 11,852 shares of the company’s stock, valued at $3,086,023.76. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Shannon M. Parisotto sold 5,046 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the transaction, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,264,241. The trade was a 51.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 165,990 shares of company stock worth $42,606,388 over the last 90 days. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.